ECE. I. Chechev

E. I. Chechev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. I. Chechev has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the radicality of surgical treatment of pediatric patients with osteosarcoma of the maxillofacial region in children

    by E. I. Chechev, I. N. Vorozhtsov, A. V. Lopatin, N. V. Babaskina, E. I. Konopleva, Y. M. Chuyko, Nikolay Sergeevich Grachev

    Introduction. Osteosarcoma of the maxillofacial region is an extremely rare variant of osteosarcoma, accounting for no more than 6–9% of all cases. Unlike tumors located in the bones of the extremities, osteosarcoma of the maxillofacial region is characterized by a lower tendency for distant metastasis. Due to the specific location of the primary lesion in the maxillofacial region, namely the proximity to vital structures, radical surgical intervention is associated with a number of difficulties; however, it is a key element of treatment that determines the prognosis of the disease. Materials and methods. The study included patients under the age of 18 years with a verified osteosarcoma of the maxillofacial region, registered between 2012 and 2024 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Healthcare of the Russian Federation. Treatment for high-grade osteosarcoma patients was conducted according to the MAP regimen (based on the EURAMOS-1 protocol). Treatment for low-grade osteosarcoma patients was limited to surgical resection of the primary lesion. Results. The study included 11 patients (6 boys and 5 girls) with a median age of 11 years. Seven tumors (63.6%) were located in the mandible and four tumors in the maxilla (36.4%). A histological examination revealed 9 (81.9%) cases of high-grade osteosarcoma and 2 (18.1%) cases of low-grade osteosarcoma. The stage distribution was as follows: stage IA, 18.1%; stage IIA, 63.6%; stage IIB, 9.0%; stage III, 9.0%. Local surgical control was performed in all the patients: R0 resection was achieved in 9 (81.9%) cases and R1 in 2 (18.1%) cases. The median follow-up was 7 years. The event-free survival was 91% at 1 year and 64% at 3 years and at 5 years. The overall survival was 100% at 1 year, 82% at 3 years, and 73% at 5 years. Conclusion. The cornerstone of treatment for patients diagnosed with osteosarcoma is radical surgery. In patients, for whom radical resection is not feasible, survival approaches zero.

  • Open Access

    EWSR1::TFCP2-rearranged rhabdomyosarcoma of the skull bones: a clinical case and a literature review

    by Il'YA V. Sidorov, A. S. Sharlai, A. E. Druy, A. V. Panferova, R. Kh. Abasov, E. I. Chechev, D. V. Shevtsov, I. N. Vorozhtsov, N. S. Grachev, P. E. Trakhtman, et al.

    Introduction. Rhabdomyosarcoma with EWSR1::TFCP2 rearrangement is a rare type of tumor with myogenic differentiation, characterized by an aggressive clinical course and difficulties in diagnosis. Our literature review highlights its key features: a predominance of craniofacial localization, an extremely unfavorable prognosis, and frequent aberrant immunophenotypic patterns. Particular attention is paid to the heterogeneity of tumors with myogenic differentiation, which include a wide range of entities with various genetic abnormalities. This calls into question the traditional diagnostic criteria for rhabdomyosarcoma and require their revision, given the lack of standardized therapy and the complexity of differential diagnosis. Clinical case. Here, we present a clinical case of rhabdomyosarcoma with EWSR1::TFCP2 rearrangement in a 12-year-old girl with primary involvement of the skull base. The tumor showed aggressive growth with the involvement of sphenoid and latticed bones and intracranial spread. Histological examination revealed an epithelioid spindle cell tumor invading bone tissue and a myogenic immunophenotype with the expression of pan-cytokeratin. The diagnosis was confirmed by FISH and high-throughput RNA sequencing, which verified the presence of EWSR1::TFCP2 chimeric transcript. Conclusion. The lack of standardized therapy and the difficulty of differential diagnosis underscore the need for further research to improve understanding, classification, and treatment of this type of rhabdomyosarcoma.

  • EXTRANASOPHARYNGEAL ANGIOFIBROMA. TWO CLINICAL CASES

    by I.N. Vorozhtsov, E.I. Chechev, N.S. Grachev

    Juvenile angiofibroma is a rare benign mesenchymal tumor, morphologically representing a vascular proliferation in a cellular, densely collagenized stroma, usually occurring in the nasopharynx, more often in adolescent boys. Recently, an increasing number of articles have been publishedon the so-called extranasopharyngeal angiofibroma (ENA), which can occur in both boys and girls. This article describes the clinical course of ENA and presents two clinical cases of extranasopharyngeal angiofibroma.


  • Open Access

    Neoadjuvant therapy of juvenile angiofibroma of the nasopharynx and base of the skull with good clinical outcome (clinical case)

    by I. N. Vorozhtsov, N. S. Grachev, E. I. Chechev, A. S. Krasnov

    Juvenile nasopharyngeal angiofibroma is a benign, highly vascularized tumor that occurs mainly in children and young men of pubertal age 9-19 years old. Often manifested by difficulty in nasal breathing and nosebleeds. We report a 16-year-old boy with complaints of a complete absence of nasal breathing, nosebleeds, snoring, nasality, exophthalmos on the right side, visual impairment. undergoing therapeutic treatment for rhinosinusitis and adenoid vegetations for 5 months and an unsuccessful attempt at adenotomy in history. When contacting the Department of Oncology and Pediatric Surgery Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology according to imaging with contrast enhancement juvenile angiofibroma of the nasopharynx IVA stage to Fisch-Andrews with a 30 % increase in volume in 2 months. The patient was initiated on neoadjuvant therapy Sirolimus as part of a pilot phase of a prospective clinical trial. After 9 months of taking the drug, there is a reduction in the tumor by 37 %, restoration of vision, clinical and radiological improvement.

  • OSTEOSARCOMA AND EWING’S SARCOMA OF THE MAXILLOFACIAL REGION IN CHILDREN: THERAPEUTIC APPROACHES AND SURGICAL LOCAL CONTROL FEATURES

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, E.I. Chechev, N.S. Grachev, N.V. Babaskina, I.N. Vorozhtsov, E.I. Konopleva

    Authors analyze bibliographical data on the treatment of osteosarcoma and Ewing's sarcoma of the maxillofacial region in children and adolescents. The role of surgical treatment in the primary lesion of this localization is analyzed in detail as well as the complex therapeutic approaches.